Tamoxifen and the uterus and endometrium.
作者信息
Cano A, Matallin P, Legua V, Tortajada M, Bonilla-Musoles F
出版信息
Lancet. 1989 Feb;1(8634):376.
PMID:18446930
Abstract
摘要
相似文献
1
Tamoxifen and the uterus and endometrium.
Lancet. 1989 Feb;1(8634):376.
2
Gynaecological aspects of tamoxifen treatment in breast cancer patients.
Cancer Treat Rev. 1997 Sep-Nov;23(5-6):289-304. doi: 10.1016/s0305-7372(97)90029-3.
3
[Tamoxifen and breast cancer: is everything known already?].
Tumori. 1998 Nov-Dec;84(6):A1-5.
4
Tamoxifen therapy--long-term results and complications.
Adv Surg. 1996;29:263-9.
5
Tamoxifen and the endometrium.
Cancer Treat Res. 1998;94:195-207. doi: 10.1007/978-1-4615-6189-7_11.
6
[Uterine pathology in women with breast cancer treated with tamoxifen].
Pathologica. 1997 Jun;89(3):223-33.
7
Tamoxifen.
Nurs Times. 2006;102(8):33.
8
MR appearance of endometrial carcinoma and mucinous cystadenoma in a postmenopausal patient treated with tamoxifen for breast cancer.
Radiat Med. 1998 Jul-Aug;16(4):315-9.
9
Tamoxifen in early breast cancer.
Lancet. 1998 Aug 1;352(9125):404. doi: 10.1016/S0140-6736(05)60502-8.
10
Tamoxifen and menopausal status: risks and benefits.
Lancet. 1996 Mar 16;347(9003):761. doi: 10.1016/s0140-6736(96)90111-7.
引用本文的文献
1
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.
2
Tumorigenic effects of tamoxifen on the female genital tract.
Clin Med Pathol. 2008;1:17-34. doi: 10.4137/cpath.s487. Epub 2008 Mar 1.
3
Tamoxifen and secondary tumours. An update.
Drug Saf. 1997 Feb;16(2):104-17. doi: 10.2165/00002018-199716020-00003.
Zotero 插件